


In the Claims:

15. (Currently Amended) A pharmaceutical composition containing
a compound as defined in Formula I



Formula I

in which;

R₁ and R₂ are the same or different and independently selected from the group consisting of; hydrogen, halogen, C₁-C₁₀ alkyl, C₁-C₁₀ substituted alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ alkoxy, C₁-C₁₀ alkenoxy, C₁-C₁₀ alkynoxy, C₁-C₁₀ alkylthio, C₁-C₁₀ alkenylthio, C₁-C₁₀ alkynylthio, C₆-C₁₀ arylthio, C₁-C₁₀ alkylsulphone, C₁-C₁₀ alkenylsulphone, C₁-C₁₀ alkynylsulphone, C₆-C₁₀ arylsulphone, C₁-C₁₀ alkylsulphoxide, C₁-C₁₀ alkenylsulphoxide, C₁-C₁₀ alkynylsulphoxide, C₆-C₁₀ arylsulphoxide, C₁-C₁₀ alkylarylthio, C₁-C₁₀ alkylarylsulphone, C₁-C₁₀ alkylarylsulphoxide, C₆-C₁₀ aryl, or C₅-C₂₀ heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R₁ and R₂ may together form a C₃-C₁₀ cycloalkyl group;

R₃ and R₄ are the same or different and independently selected from hydrogen, halogen, C₁-C₂₀ alkyl, C₃-C₇ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, C₁-C₄ alkenoxy, C₁-C₄ alkynoxy, C₁-C₄ alkylthio, C₁-C₄ alkenylthio, C₁-C₄ alkynylthio, C₁-C₁₀ alkylsulphone, C₁-C₁₀ alkenylsulphone, C₁-C₁₀ alkynylsulphone, C₆-C₁₀ arylsulphone, C₁-C₁₀ alkylsulphoxide, C₁-C₁₀ alkenylsulphoxide, C₁-C₁₀ alkynylsulphoxide, C₆-C₁₀ arylsulphoxide, C₁-C₁₀ alkylarylthio, C₁-C₁₀ alkylarylulphone, C₁-C₁₀ alkylarylulphoxide, C₆-C₁₅ aryl, C₅-C₂₀ heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R₅ is chosen from the group consisting of; nitro, cyano, -CH₂CN, -COMe, acetic acid, halogen, sulphonie acid, or -SO₂CH₃; aldehyde, carboxylic acid or ester, phosphonic acid or ester;

R₆ is chosen from the group consisting of; hydrogen, C₁-C₅ alkyl, halogen, CN, CO₂H, CHF₂, CH₂F or CF₃;

Z is chosen from CR₇ or N;

R₇ is chosen from the group consisting of; H, halogen or C₁-C₅ alkyl;

R₈ is chosen from the group consisting of; hydrogen, C₁-C₅ alkyl, halogen, CHF₂, CH₂F or CF₃;

~~X is chosen from the group consisting of; -NH-, -O-, -S-, -SO-, -SO₂-, -Se-, -Te- or -S-S-~~



~~Y is chosen from the group consisting of; hydrogen, hydroxy, CH₂OH, methoxy, NH₂, unbranched, branched or cyclic C₄-C₅ alkyl, unbranched, branched or cyclic NH(C₄-C₈); unbranched, branched or cyclic N(C₄-C₈)₂, NH(C₆aryl), N(C₆aryl)₂, or -NH(C₁-C₁₀ heteroaryl); and N(C₅-C₁₀ heteroaryl)₂, C₅-C₁₀ heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of R^a which groups may be the same or different;~~

~~Z is chosen from the group consisting of; C, N, or O;~~

R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO_2H , CHO, NO_2 , -NH_2 , $\text{-NH(C}_1\text{-C}_4\text{)}$, $\text{N(C}_1\text{-C}_4\text{)}_2$, $\text{-NH(C}_6\text{ aryl)}$, $\text{-N(C}_6\text{ aryl)}_2$, $\text{-NH(C}_5\text{-C}_{10}\text{ heteroaryl)}$, and $\text{-N(C}_5\text{-C}_{10}\text{ heteroaryl)}_2$; or a pharmaceutically acceptable salt thereof.

16. - 17. (Cancelled).

18. (Currently Amended) A compound as defined by Formula I:



Formula I

in which;

R_1 and R_2 are the same or different and independently selected from the group consisting of: hydrogen, halogen, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ substituted alkyl, $\text{C}_2\text{-C}_{10}$ alkenyl, $\text{C}_2\text{-C}_{10}$ alkynyl, $\text{C}_1\text{-C}_{10}$ alkoxy, $\text{C}_1\text{-C}_{10}$ alkenoxy, $\text{C}_1\text{-C}_{10}$ alkynoxy, $\text{C}_1\text{-C}_{10}$ alkylthio, $\text{C}_1\text{-C}_{10}$ alkenylthio, $\text{C}_1\text{-C}_{10}$ alkynylthio, $\text{C}_6\text{-C}_{10}$ arylthio, $\text{C}_1\text{-C}_{10}$ alkylsulphone, $\text{C}_1\text{-C}_{10}$ alkenylsulphone, $\text{C}_1\text{-C}_{10}$

alkynylsulphone, C₆-C₁₀ arylsulphone, C₁-C₁₀ alkylsulphoxide, C₁-C₁₀ alkenylsulphoxide, C₁-C₁₀ alkynylsulphone, C₆-C₁₀ arylsulphoxide, C₁-C₁₀ alkylarylthio, C₁-C₁₀ alkylarylulphone, C₁-C₁₀ alkylarylulphoxide, C₆-C₁₀ aryl, or C₅-C₂₀ heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R₁ and R₂ may together form a C₃-C₁₀ cycloalkyl group;

R₃ and R₄ are the same or different and independently selected from hydrogen, halogen, C₁-C₂₀ alkyl, C₃-C₇ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, C₁-C₄ alkenoxy, C₁-C₄ alkynoxy, C₁-C₄ alkylthio, C₁-C₄ alkenylthio, C₁-C₄ alkynylthio C₁-C₁₀ alkylsulphone, C₁-C₁₀ alkenylsulphone, C₁-C₁₀ alkynylsulphone, C₆-C₁₀ arylsulphone, C₁-C₁₀ alkylsulphoxide, C₁-C₁₀ alkenylsulphoxide, C₁-C₁₀ alkynylsulphoxide, C₆-C₁₀ arylsulphoxide, C₁-C₁₀ alkylarylthio, C₁-C₁₀ alkylarylulphone, C₁-C₁₀ alkylarylulphoxide, C₆-C₁₅ aryl, C₅-C₂₀ heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R₅ is chosen from the group consisting of; nitro, cyano, -CH₂CN, -COMe, or acetic acid, ~~halogen, sulphonic acid, -SO₂CH₃, aldehyde, carboxylic acid or ester, phosphonic acid or ester;~~

R₆ is chosen from the group consisting of; hydrogen, C₁-C₅ alkyl, halogen, CN, CO₂H, CHF₂, CH₂F or CF₃;

~~R₇ is chosen from the group consisting of; H, halogen or C₁-C₅ alkyl;~~

R₈ is chosen from the group consisting of; hydrogen, C₁-C₅ alkyl, halogen, CHF₂, CH₂F or CF₃;

~~X is chosen from the group consisting of; -NH-, -O-, -S-, -SO-, -SO₂-, -Se-, -Te- or -S-S-~~

~~Y is chosen from the group consisting of; hydrogen, hydroxy, or -CH₂OH, methoxy, NH₂, unbranched, branched or cyclic C₄-C₈ alkyl, unbranched, branched or cyclic NH(C₄-C₈); unbranched, branched or cyclic N(C₄-C₈)₂, NH(C₆aryl), N(C₆aryl)₂, -NH(C₁-C₁₀ heteroaryl);~~





and $\text{N}(\text{C}_5\text{-C}_{10}\text{ heteroaryl})_2$, $\text{C}_5\text{-C}_{10}\text{ heteroaryl}$ wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of R^a which groups may be the same or different;

Z is chosen from the group consisting of: C, N, or O; CR_7 or N;

R_7 is H or $\text{C}_1\text{-C}_5$ alkyl;

R^a represents a member selected from: hydrogen, halogen, -CN , OH , CO_2H , CHO , NO_2 , -NH_2 , $\text{-NH}(\text{C}_1\text{-C}_4)$, $\text{N}(\text{C}_1\text{-C}_4)_2$, $\text{-NH}(\text{C}_6\text{aryl})$, $\text{-N}(\text{C}_6\text{ aryl})_2$, $\text{-NH}(\text{C}_5\text{-C}_{10}\text{ heteroaryl})$, and $\text{-N}(\text{C}_5\text{-C}_{10}\text{ heteroaryl})_2$; or a pharmaceutically acceptable salt thereof,

with the proviso that the compound is not one of:




wherein A is -CN or -NO_2 , and B is -CN , -NO_2 or $\text{-SO}_2\text{CH}_3$.









19. (Original) A compound according to claim 18, wherein R₁ or/and R₂ are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, S-1-methyl-propyl, S-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -(CH₂)₂SMe, (R)-CH₂SCH₂Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl.
20. (Previously Presented) A compound according to claim 18, wherein R₃ is chosen from the group consisting of hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R₄.
21. (Previously Presented) A compound according to claim 18, wherein R₄ is H, methyl, or forms a keto group together with R₃.
22. (Currently Amended) A compound according to claim 18, wherein R₅ is NO₂, CN, or CH₂CN ~~or~~ CO₂H.
23. (Previously Presented) A compound according to claim 18, wherein R₆ is Me or CF₃.
24. (Previously Presented) A compound according to claim 18, wherein R₇ is H or Me.
25. (Previously Presented) A compound according to claim 18, wherein R₈ is H or methyl.
26. (Cancelled)










27. (Currently Amended) A compound according to claim 18,
wherein Y is H, -OH, ~~OMe, N(CH₂CH₃)₂, piperidine, or 4-~~
~~nitro-2-ylamino.~~
28. (Cancelled)
29. (Currently Amended) A compound according to claim 18,
wherein the compound is chosen from the group consisting
of:
2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-
1-ol;
[1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-
methanol
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenyl-
propan-1-ol;
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;
2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;
[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;
(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;
2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-
ol;
[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-
methanol;
(S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;
(S)-2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-
propan-1-ol;
(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;
(DL)-3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-
ylamino)-propan-1-ol;
(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic
acid;
(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;









~~2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-ol;~~
2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-ol;
(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-
benzonitrile;
4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-
benzonitrile;
(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-
benzonitrile;
(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
benzonitrile;
(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
benzonitrile;
[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
phenyl]-acetonitrile;
[4-((R)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
phenyl]-acetonitrile;
[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-
trifluoromethyl-phenyl]-acetonitrile;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-
benzonitrile;
6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-
nicotinonitrile;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-
benzonitrile;
and compounds having the formula:





















in which R₉, R₆ and Z are as defined in the following table:











R9	R6	Z
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH

R9	R6	Z		
	CF ₃	CH		
	CF ₃	CH		
	CF ₃	CH		
	CF ₃	CH		
	CF ₃	CH		
	CF ₃	CH		
	CF ₃	CH		
	CF ₃	CH		
	CF ₃	CH		












R9	R6	Z
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH

R9	R6	Z
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CH ₃	N
	CH ₃	N
	CH ₃	N



R9	R6	Z
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N

R9	R6	Z
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	CH

[illegible]

R9	R6	Z
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH

[illegible]

R9	R6	Z
	CH ₃	CH
	CH ₃	CH

~~4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzoic~~
~~acid,~~


~~(6 Methyl 5 nitro 2 pyridin 2 ylamino) butionic methyl~~
~~ester,~~

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-
benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile
(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol
3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
~~2-(6-Methyl-5-nitro-pyridin-2-ylsulfanyl)-ethanol~~
~~[1-(4-Fluoro-3-methyl-phenylamino)-cyclopentyl]-methanol~~
~~1-[4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-phenyl]-ethanone~~
~~1-[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-ethanone~~
~~1-[4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-phenyl]-ethanone~~
[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol
2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
2,2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol
4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile
(R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol
4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzonitrile
[1-(4-Nitro-phenylamino)-cyclopentyl]-methanol
(S)-2-(4-Nitro-phenylamino)-pentan-1-ol
~~(S)-4-Methyl-2-(4-nitro-phenylamino)-pentan-1-ol~~
[1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol
(S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol
(S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol

30. (Previously Presented) A compound according to claim 18, wherein R_1 or R_2 is a C_6 - C_{10} arylthio comprising an aryl-substituted sulfur-containing C_1 - C_{10} alkyl group.
31. (Previously Presented) A compound according to claim 18, wherein in R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.
32. (New) A method of treating a disease caused by a disturbance in the activity of the androgen receptor comprising administering a compound comprising Formula I to a subject in need thereof, wherein Formula I is defined as:



Formula I

in which;

R_1 and R_2 are the same or different and independently selected from hydrogen, halogen, C_1 - C_{10} alkyl, C_1 - C_{10} substituted alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_1 - C_{10} alkoxy, C_1 - C_{10} alkenoxy, C_1 - C_{10} alkynoxy, C_1 - C_{10} alkylthio, C_1 - C_{10} alkenylthio, C_1 - C_{10} alkynylthio, C_6 - C_{10} arylthio, C_1 - C_{10} alkylsulphone, C_1 - C_{10} alkenylsulphone, C_1 - C_{10} alkynylsulphone, C_6 - C_{10} arylsulphone, C_1 - C_{10} alkylsulphoxide, C_1 - C_{10} alkenylsulphoxide, C_1 - C_{10} alkynylsulphoxide, C_6 - C_{10} arylsulphoxide, C_1 - C_{10} alkylarylthio, C_1 - C_{10} alkylarylsulphone, C_1 - C_{10} alkylarylsulphoxide, C_6 - C_{10} aryl, or C_5 - C_{20} heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or R_1 and R_2 may together form a C_3 - C_{10} cycloalkyl group;

R₃ and R₄ are the same or different and independently selected from hydrogen, halogen, C₁-C₂₀ alkyl, C₃-C₇ cycloalkyl, C₂-C₄ alkenyl; C₂-C₄ alkynyl, C₁-C₄ alkoxy, C₁-C₄ alkenoxy, C₁-C₄ alkynoxy, C₁-C₄ alkylthio, C₁-C₄ alkenylthio, C₁-C₄ alkynylthio, C₁-C₁₀ alkylsulphone, C₁-C₁₀ alkenylsulphone, C₁-C₁₀ alkynylsulphone, C₆-C₁₀ arylsulphone, C₁-C₁₀ alkylsulphoxide, C₁-C₁₀ alkenylsulphoxide, C₁-C₁₀ alkynylsulphoxide, C₆-C₁₀ arylsulphoxide, C₁-C₁₀ alkylarylthio, C₁-C₁₀ alkylarylulphone, C₁-C₁₀ alkylarylulphoxide, C₆-C₁₅ aryl, C₅-C₂₀ heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^a which groups may be the same or different; or can together form a keto group;

R₅ is chosen from nitro, cyano, -CH₂CN, -COMe, or -SO₂CH₃;

R₆ is chosen from the group consisting of; hydrogen, C₁-C₅ alkyl, halogen, CN, CO₂H, CHF₂, CH₂F or CF₃;

R₈ is chosen from the group consisting of; hydrogen, C₁-C₅ alkyl, halogen, CHF₂, CH₂F or CF₃;

X is -NH-;





Y is chosen from hydroxy, or -NH(C₁-C₁₀ heteroaryl);

Z is chosen from CR₇ or N;

R₇ is H or C₁-C₅ alkyl;

R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO₂H, CHO, NO₂, -NH₂, -NH(C₁-C₄); N(C₁-C₄)₂, -NH(C₆aryl), -N(C₆aryl)₂, -NH(C₅-C₁₀ heteroaryl), and -N(C₅-C₁₀ heteroaryl)₂; or a pharmaceutically acceptable salt thereof,

with the proviso that the compound is not one of:



wherein A is -CN or -NO₂, and B is -CN, -NO₂ or -SO₂CH₃.


33. (New) A method according to claim 32, wherein R₁ or/and R₂ are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, S-1-methyl-propyl, S-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -(CH₂)₂SMe, (R)-CH₂SCH₂Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl.
34. (New) A method according to claim 32, wherein R₃ is chosen from the group consisting of hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R₄.

35. (New) A method according to claim 32, wherein R_4 is H, methyl, or forms a keto group together with R_3 .
36. (New) A method according to claim 32, wherein R_5 is NO_2 , CN, or CH_2CN .
37. (New) A method according to claim 32, wherein R_6 is Me or CF_3 .
38. (New) A method according to claim 32, wherein R_7 is H or Me.
39. (New) A method according to claim 32, wherein R_8 is H or methyl.
40. (New) A method according to claim 32, wherein Y is -OH.
41. (New) A method according to claim 32, wherein the compound is chosen from the group consisting of:
2-Methyl-2-(4-nitro-3-trifluoromethyl-phenylamino)-propan-1-ol;
[1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-methanol
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenylpropan-1-ol;
(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;
2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;
[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;
(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;
2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;
[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino) 2-phenyl-ethanol;
(S)-2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-
propan-1-ol;
(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;
(DL)-3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-
ylamino)-propan-1-ol;
(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic
acid;
(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;
2-(2,3-Dimethyl-4-nitro-phenylamino)-2-methyl-propan-1-ol;
(S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-
benzonitrile;
4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-
benzonitrile;
(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-
benzonitrile;
(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
benzonitrile;
(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
benzonitrile;
[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
phenyl]-acetonitrile;
[4-((R)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-
phenyl]-acetonitrile;
[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-
trifluoromethyl-phenyl]-acetonitrile;
4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-
benzonitrile;
6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-
nicotinonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-
benzonitrile;





and compounds having the formula:


















in which R₉, R₆ and Z are as defined in the following table:












R ₉	R ₆	Z
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH



R9	R6	Z
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH
	CF ₃	CH

R9	R6	Z
	CF ₃	CH
	CH ₃	N
	CH ₃	N
	CH ₃	N

R9	R6	Z
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N

R9	R6	Z
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	N
	CH ₃	CH

R9	R6	Z
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH
	CH ₃	CH

R9	R6	Z
	CH ₃	CH
	CH ₃	CH

2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;

4-((R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile

4-((R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol

3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

[1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol

2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol

2,2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol

4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile

(R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol

4-((R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-
2-trifluoromethyl-benzonitrile
[1-(4-Nitro-phenylamino)-cyclopentyl]-methanol
(S)-2-(4-Nitro-phenylamino)-pentan-1-ol
[1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol
(S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol
(S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol

42. (New) A method according to claim 32, wherein R_1 or R_2 is a C_6 - C_{10} arylthio comprising an aryl-substituted sulfur-containing C_1 - C_{10} alkyl group.
43. (New) A method according to claim 32, wherein in R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.